Questions About Cancer? 1-800-4-CANCER
  • View entire document
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Gestational Trophoblastic Disease Treatment (PDQ®)

Changes to This Summary (04/25/2014)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information About Gestational Trophoblastic Disease

Added Ngan et al. as reference 1.

Cellular Classification of Gestational Trophoblastic Disease

Added Altieri et al. as reference 1.

Treatment Option Overview

Added Sita-Lumsden et al. as reference 1.

High-Risk Gestational Trophoblastic Neoplasia (FIGO Score ≥7) Treatment

Added text to state that routinely when cisplatin plus etoposide was added to EMA/CO (i.e., etoposide, methotrexate, and dactinomycin/cyclophosphamide and vincristine), a 9% improvement was reported in the survival results of these high-risk patients (cited Alifrangis et al. as reference 6).

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.

  • Updated: April 25, 2014